Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 5, 2002, Pages 2283-2289

  Chan, Dick C ^a   Watts, Gerald F ^a   Hugh R Barrett, P ^a   Mori, Trevor A ^a   Beilin, Lawrence J ^a   Redgrave, Trevor G ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LATHOSTEROL; LEUCINE; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BOLUS INJECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GAS CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SECRETION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036092983     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.5.8455     Document Type: Article

References (57)

1. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease
2. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity
3. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men
4. Role of insulin resistance in human disease
5. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey
6. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service
7. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
8. Statin trials and goals of cholesterol-lowering therapy
9. Lipoprotein metabolism
10. Substrate delivery as a determinant of hepatic apoB secretion
11. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects
12. Role of cholesterol in regulating apolipoprotein B secretion by the liver
13. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males
14. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis
15. Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man
16. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects
17. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state
18. Metabolic basis of hypotriglyceridemic effects of insulin in normal men
19. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
20. Blood volume
21. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B
22. Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma
23. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
24. Analysis of native and oxidized low-density lipoprotein oxysterols using gas chromatography-mass spectrometry with selective ion monitoring
25. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
26. Preliminary model for human lipoprotein metabolism in hyperlipoproteinemia
27. Metabolic modes of action of the statins in the hyperlipoproteinemias
28. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion
29. Effects of simvastatin on apo B metabolism and LDL subfraction distribution
30. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia
31. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production
32. Dyslipidaemia and obesity
33. Acute hyperinsulinaemia decreases cholesterol synthesis less in subjects with non-insulin-dependent diabetes mellitus than in non-diabetic subjects
34. Acute hyperinsulinemia decreases hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in normolipidaemic, non-diabetic subjects
35. Lipoprotein lipase in diabetes
36. In vivo stimulation of low-density lipoprotein degradation by insulin
37. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM
38. Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration
39. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes
40. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans
41. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
42. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase
43. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
44. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs
45. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells
46. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin
47. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes
48. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM
49. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools
50. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages
51. Feeding of lovastatin to rats increases the activity of the hepatic mitochondrial outer carnitine palmitoyltransferase
52. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins
53. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men
54. Glucose clamp technique: A method for quantifying insulin secretion and resistance
55. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men
56. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity
57. Clinical lipidology at the end of the millennium